LATAM MedTech Insights

In this episode, we dissect the sudden and disruptive launch of ANVISA's new mandatory digital submission platform in Brazil, which has caught many international MedTech manufacturers off guard. We explore the immediate operational challenges, from language barriers to technical glitches, and discuss the strategic implications for companies planning to enter or expand within Latin America's largest market. We delve into the real-world impact through the case of a European firm whose multi-million dollar product launch was jeopardized overnight. Their meticulously prepared technical dossier was rendered incompatible with the new system, forcing them into a desperate race against time to reformat and resubmit, highlighting the critical need for regulatory agility and expert local representation. 本期干货 1. What are the three most critical technical changes in ANVISA's new PDR platform? 2. Why was no grace period offered for such a major regulatory transition? 3. How does this shift specifically impact the approval timeline for high-risk devices? 4. What are the hidden documentation requirements not listed in the official guidance? 5. How can AI-powered tools accelerate the adaptation of your technical dossier for the new format? 6. Is your current local representative equipped to handle this digital-only transition? 7. What are the key financial risks associated with submission errors on the new platform? 8. How can you leverage this regulatory shift as a competitive advantage? Struggling with market access in Latin America? Pure Global offers end-to-end regulatory consulting, leveraging local expertise and advanced AI to streamline your path to market in over 30 countries, including Brazil, Mexico, and Colombia. Don't let regulatory surprises derail your launch. Contact our experts at [email protected] or visit https://pureglobal.com/ to secure your market presence.

This week, we dive into the groundbreaking news from Mexico's regulatory agency, COFEPRIS. A new fast-track "equivalency agreement" has been announced, set to revolutionize market access for medical device companies with existing US FDA or European CE Mark approval. This episode unpacks the details of this new pathway, exploring the immense opportunities it creates for international MedTech firms. We break down what this regulatory shift means for your business strategy in Latin America. This isn't just a minor update; it's a strategic move by Mexico to become the primary landing spot for MedTech innovation and investment in the region. We analyze the immediate benefits and the potential long-term competitive advantages for companies that act quickly. ## What You'll Learn: * What is the new COFEPRIS "equivalency agreement" and how does it actually work? * Which specific device classes are eligible for this new fast-track process? * How does this change Mexico's position against other LATAM markets like Brazil? * What are the critical documentation requirements needed to leverage your existing FDA or CE approval? * Are there any hidden pitfalls or new compliance details to watch out for in this streamlined process? * How can this new rule drastically reduce your company’s time-to-market and registration costs? * What does this mean for local Mexican manufacturers and the competitive landscape? * Is this the first step toward broader regulatory harmonization across Latin America? Navigating these complex changes requires local expertise and a global perspective. Pure Global offers end-to-end regulatory consulting for MedTech companies, combining local experts with AI tools to streamline global market access. We act as your local representative to ensure you can capitalize on new regulations efficiently. To learn how we can accelerate your entry into the Mexican market, contact us at [email protected] or visit https://pureglobal.com/.

This week, we dissect the groundbreaking news from Brazil's ANVISA: a new fast-track approval pathway for AI-powered medical devices. This move promises to slash approval times and revolutionize the digital health landscape, but the opportunities are wrapped in complex new challenges. We go beyond the headlines to explore the intricate new requirements for clinical data, cybersecurity, and local data privacy laws that could derail even the most prepared global companies. Discover why this "shortcut" might be a longer road than expected without the right local strategy. A specific case: A successful European AI diagnostic tool, fully approved in the EU, gets rejected by ANVISA's new fast-track system. The fatal flaw? Its clinical data wasn't validated on Brazil's diverse population demographics, making it unusable in the local context. This is the exact pitfall we help you avoid. Key Takeaways This Episode: - What are the three specific types of AI software ANVISA is prioritizing? - Why might the 90-day approval promise be misleading for foreign manufacturers? - How does Brazil's LGPD data privacy law create new compliance traps in the fast-track application? - What's the number one mistake companies make when submitting clinical data for the Brazilian market? - How can you prove your algorithm is free from demographic bias for ANVISA's review? - Which specific cybersecurity protocols are now mandatory for the fast-track application? - Is it now easier or harder for startups to compete with established players under this new system? Navigating the complexities of market access in Latin America requires localized expertise and a strategic partner. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, using local experts and advanced AI to streamline your path to market. To tackle challenges like ANVISA's new regulations and accelerate your entry into Brazil, contact us at [email protected] or visit https://pureglobal.com/.

This week, we dive into a major regulatory shift in Brazil that's sending shockwaves through the digital health sector. ANVISA, the national health surveillance agency, has just released RDC 899, a groundbreaking resolution that imposes stringent new cybersecurity and data privacy rules for all Software as a Medical Device (SaMD). This update creates immediate challenges for MedTech companies, especially those leveraging AI and machine learning. The resolution requires deep integration with Brazil's data protection laws (LGPD) and demands unprecedented transparency into algorithm validation. We break down the core components of RDC 899 and what they mean for your products, whether you're seeking new registration or preparing for a renewal. A European AI diagnostics company, with a device already successful in the Brazilian market, is now facing a critical challenge. Their upcoming registration renewal requires them to retroactively create an entire cybersecurity risk portfolio and provide detailed validation data for their proprietary algorithms. This unexpected task threatens to delay their renewal, potentially costing them millions in revenue and market position. How can you avoid this costly pitfall? Key Takeaways This Episode: * What are the three mandatory documents now required under ANVISA's RDC 899? * How does Brazil's data protection law, the LGPD, now directly impact your SaMD's software architecture? * For AI-driven devices, what specific information about your training datasets must now be submitted to ANVISA? * What is the immediate risk for devices that are already registered and approaching their renewal date? * How can you turn this new regulatory hurdle into a competitive advantage in the Brazilian market? * What are the unwritten expectations from ANVISA when reviewing these new cybersecurity files? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI and data tools to streamline global market access. We act as your local representative in over 30 markets, including Brazil, ensuring you can navigate complex changes like RDC 899 without delaying your growth. Don't let regulatory surprises derail your launch. Contact us at [email protected] or visit https://pureglobal.com/ to secure your market presence.

This week on LATAM MedTech Insights, we dissect the latest 2025 medical device registration guidance from Brazil's ANVISA. While the new framework aims to streamline market access, it has introduced a host of undocumented challenges that are causing significant delays for international manufacturers. We explore the gap between the official regulations and the practical hurdles companies are facing right now. From the specific demands of the new digital submission portal to the increased technical scrutiny placed on local representatives, this episode provides a crucial look at the unwritten rules of Brazilian MedTech regulation. We uncover the real reasons behind recent submission rejections and offer insights into how companies can avoid common pitfalls and accelerate their path to market in Latin America's largest economy. **Case Study:** A US-based orthopedic device company prepared their ANVISA submission based on their recent FDA 510(k) clearance. They were confident in their data, but their application was stalled for months. The issue? Their designated Brazil Registration Holder (BRH) was unable to adequately respond to ANVISA's technical questions regarding the specific biomechanical properties of the device, a level of scrutiny the company had never anticipated, forcing them to find a new, technically proficient local partner and restart the clock on their review. **Key Takeaways This Episode:** * Is your technical dossier truly prepared for ANVISA's new, unwritten formatting rules for 2025? * How can you adapt your existing FDA or CE Mark data to satisfy Brazil-specific risk analysis requirements? * Is your chosen Brazil Registration Holder (BRH) merely an administrative contact, or a true technical expert? * What are the most common, unexpected reasons for rejection under the new digital submission system? * How do you build a realistic timeline that accounts for unpredictable INMETRO certification delays? * Are you prepared for ANVISA's increasingly deep technical questions during the review phase? Navigating these regulatory mazes is our expertise. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, combining deep local expertise in markets like Brazil with advanced AI tools to streamline your global market access. Don't let regulatory hurdles derail your launch. Contact us at [email protected] or visit https://pureglobal.com/ to learn how we can help.